Paper Details

  1. Home
  2. Paper Details

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

Author: , BurnettA K, ClarkR E, GoldstoneA H, HutchinsonR M, SmithA G, WheatleyK

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

In a study of 1314 people with acute myeloid leukemia (AML), different initial chemotherapy regimens were compared. The chemotherapy regimen with daunorubicin, cytarabine, and thioguanine (DAT) was more effective in achieving remission than the other regimens. However, there was no difference in survival between the groups after 5 years. Adding granulocyte colony-stimulating factor (G-CSF) to support the immune system did not improve remission rates or survival. Similarly, there was no difference in survival, relapse, or disease-free survival between those who received three cycles of chemotherapy versus six cycles. Giving interferon for 12 months did not improve outcomes. These findings suggest that the choice of initial chemotherapy regimen for AML is important, but extending chemotherapy beyond three cycles or using interferon does not appear to benefit patients.
Paper Details　
Original Abstract of the Article :
In an attempt to improve induction chemotherapy for older patients with acute myeloid leukemia (AML),1314 patients were randomized to 1 of 3 induction treatments for 2 courses of DAT (daunorubicin, cytarabine, and thioguanine) 3 + 10, ADE (daunorubicin, cytarabine, and etoposide) 10 + 3 + 5, or MAC ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/11520775

データ提供：米国国立医学図書館（NLM）

Improving Treatment Outcomes in Acute Myeloid Leukemia

The fight against acute myeloid leukemia (AML) is a constant battle against a relentless enemy. This study explores new approaches to improving treatment outcomes for older patients with AML, a particularly challenging group. The researchers conducted a large-scale randomized trial comparing different induction chemotherapy regimens and investigating the potential benefits of supportive care measures like granulocyte colony-stimulating factor (G-CSF).

Finding Effective Treatment Strategies

The study found that the DAT induction regimen (daunorubicin, cytarabine, and thioguanine) was significantly more effective than ADE (daunorubicin, cytarabine, and etoposide) or MAC (mitoxantrone-cytarabine) in achieving remission. However, there was no significant difference in overall survival at 5 years between the different induction regimens. The study also found that G-CSF did not improve remission rates or survival but did reduce the time needed for neutrophil recovery. Finally, the study explored the impact of different maintenance treatment durations and found no significant difference in relapse risk, disease-free survival, or overall survival between the groups.

Personalized Treatment Approaches

This research highlights the need for personalized treatment approaches for AML, considering factors like age, treatment history, and individual patient characteristics. While DAT proved to be more effective in achieving remission in this study, the lack of significant differences in overall survival suggests that further research is needed to identify optimal treatment strategies for older patients.

Dr.Camel's Conclusion

This study emphasizes the importance of ongoing research to develop more effective treatments for AML. Like a persistent camel navigating a vast and challenging desert, researchers must continue to explore new approaches to combat this devastating disease. The study also highlights the need for individualized treatment plans tailored to the specific needs of each patient.

Date :
  1. Date Completed 2001-10-04
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

11520775

DOI: Digital Object Identifier

S0006-4971(20)61398-2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.